When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
Sarepta Therapeutics (SRPT) had its "sell" rating reaffirmed by HC Wainwright. They now have a $5.00 price target on the stock.
Roche to start new Elevidys study following setback in Europe [Yahoo! Finance]
Sarepta Therapeutics (SRPT) had its price target raised by Royal Bank Of Canada from $18.00 to $19.00. They now have a "sector perform" rating on the stock.
Sarepta Therapeutics (SRPT) had its price target raised by Wedbush from $29.00 to $35.00. They now have an "outperform" rating on the stock.